Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2022. Part I
Afiliação
(1) Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil; Instituto Americas de Ensino e Pesquisa, Rio de Janeiro, RJ, Brazil.
(2) Hospital Professor Edgar Santos da Universidade Federal da Bahia (HUPES-UFBA), Salvador, BA, Brazil.
(3) Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, SP, Brazil.
(4) Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil.
(5) A Beneficência Portuguesa de São Paulo (BP), São Paulo, SP, Brazil.
(6) Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil.
Resumo
The Guidelines Project, an initiative of the Brazilian Medical Association, aims to combine information from the medical field to standardize producers to assist the reasoning and decision-making of doctors. The information provided through this project must be assessed and criticized by the physician responsible for the conduct that will be adopted, depending on each patient's conditions and clinical status. The data contained in the following articles were prepared by and are recommended by the Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH). Even so, all possible medical approaches should be evaluated by the physician responsible for treatment depending on patient's characteristics and clinical status.
Questions: What is the age limit for autologous stem cell transplantation? What is the best combination for the patient's initial treatment eligible for autologous stem cell transplantation: three or four drugs from different therapeutic classes? Is high-dosage therapy with melphalan 200mg/m2 superior to busulfan and melphalan? Would two transplants be better than one transplant? Is post-transplant consolidation indicated for all patients? Is post-transplant maintenance indicated for all patients? Is there a role for allogeneic transplantation?